Genetic Variation in CYP2B6, UGT1A4 and Sulfotransferases Is Associated with Disease-Free Survival in South African Breast Cancer Patients Treated with Tamoxifen

This study examines the impact of genetic variations in CYP2B6, UGT1A4, and sulfotransferases on disease-free survival (DFS) in 166 South African breast cancer patients treated with tamoxifen. It finds that the CYP2B6*1/*6 or *4/*9 genotype is associated with improved DFS, while SULT1E1 rs3775779 heterozygosity is linked to reduced DFS. The research underscores the significance of genetic factors in optimizing tamoxifen therapy, suggesting that phase II enzymes may play a crucial role in tamoxifen pharmacogenetics in African populations. The study calls for more inclusive pharmacogenomic research to enhance personalized treatment strategies and reduce breast cancer mortality.